Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tscan Therapeutics Inc.
Headquarters: Waltham, MA, United States of America
Website: http://www.tscan.com
Year Founded: 2018
Status: Public
Industry Sector: HealthTechnology
CEO: Gavin MacBeath, PhD
Number Of Employees: 194
Enterprise Value: $147,721,868
PE Ratio: -1.06
Exchange/Ticker 1: NASDAQ:TCRX
Exchange/Ticker 2: N/A
Latest Market Cap: $68,474,600
BioCentury | Mar 29, 2025
Management Tracks
Aurion names Arnaud Lacoste CEO
Plus: David de Vries named CEO of Tr1x, and updates from Crispr, Pacbio, Alvotech and Tscan
BioCentury | Dec 19, 2024
Discovery & Translation
Science Spotlight: Platelets as targeted protein degraders
BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity
BioCentury | Sep 4, 2024
Discovery & Translation
The inextricable linkage of biomarkers and target discovery
Back to School 2024: How biomarkers can help validate targets while bringing precision medicine to I&I and neurology
BioCentury | Sep 4, 2024
Discovery & Translation
Immunoproteomics upstage genomics in I&I target discovery
Back to School 2024 identifies the target classes emerging in inflammation and immunology, and the technologies used to find them
BioCentury | Jun 18, 2024
Management Tracks
Arvinas promotes Taylor to president of R&D, Cacace to CSO
Plus: Enterprise hires Renu Gupta as CMO, and chairman retires at TScan
BioCentury | Apr 30, 2024
Management Tracks
New CEOs at Evox and George Medicines
Plus: Stoke hires Thomas Leggett as CFO, and updates from TScan, Rinri, Tevogen and more
BioCentury | Apr 19, 2024
Finance
Public equity report: Depression data drive Intra-Cellular’s $500M raise
Plus public offerings for Biohaven and TScan, and PIPEs for Cullinan and Zura
BioCentury | Feb 9, 2024
Management Tracks
Terns names Amy Burroughs CEO
Plus: Disc hires Jean Franchi as CFO, promotes Jonathan Yu to COO, and updates from Domain, Enable Injections and Alchemab
BioCentury | Jan 31, 2024
Management Tracks
George Daneker to head clinical oncology at Myriad
Plus: TScan hires Jason Amello as CFO, and updates from CytoDyn, enGene and the Scleroderma Research Foundation
BioCentury | Dec 5, 2023
Management Tracks
Glucksmann at the helm at Sensorium
Plus: CEO, CMO out at Theseus and updates from Zenas, Nanoscope, Immunitas and more
Items per page:
1 - 10 of 33